The cytochrome P450, epoxide hydrolase, and glutathione S-transferase enzyme families play an important part in the metabolism of many carcinogens and anti-cancer drugs. The expression of two forms of cytochrome P450 (P450 1A and P450 3A), epoxide hydrolase and of the a, [t, and a forms of glutathione S-transferase in normal colon, colonic adenomas, and adenocarcinoma of the colon were studied by immunohistochemistry. This allowed the precise cellular site and distribution of each enzyme to be determined. Expression of all the xenobiotic metabolising enzymes studied was almost wholly confined to the epithelial cells, whether in normal, adenoma or carcinoma samples, except that cytochrome P450 3A was also identified in mast cells and glutathione S-transferase 3 was also present in chronic inflammatory cells. Cytochrome P450 was present in only a small proportion of normal colon samples, whereas epoxide hydrolase and glutathione S-transferase [t were identified in about half, and glutathione S-transferase a and 3 in most normal samples. By contrast all the enzyme forms studied were expressed in virtually all adenomas and in over halfthe carcinomas. These results suggest that cytochrome P450 1A and cytochrome P450 3A are more specific markers of colonic neoplasia than epoxide hydrolase or glutathione Stransferases a, [i, and a. 
Colon cancer is the most common malignant tumour of the gastrointestinal tract and is one of the commonest causes of death from cancer. Colonic carcinomas are often intrinsically resistant to anti-cancer drugs, and these tumours respond poorly to anti-cancer drugs. Recent evidence has shown that the expression of enzymes participating in biotransformation may play a part in tumour drug-resistance.' 2 Moreover, the same group of xenobiotic metabolising enzymes are probably involved in the development of colonic carcinoma.35
The colonic epithelium is in continuous contact with potentially carcinogenic compounds, which enter the body usually as part of the diet. These xenobiotics may be activated or detoxified by phase I and phase II biotransformation enzymes including cytochromes P450, epoxide hydrolases, and glutathione S-transferases. 67 Metabolism may occur in the gastrointestinal tract, including the colon or in the liver, or both.
Cytochromes P450 are a multi-gene superfamily of haem containing enzymes that catalyse the oxidative metabolism of many compounds. Their substrates are endogenous compounds such as steroids and prostaglandins as well as many xenobiotics such as carcinogens, mutagens, and drugs including anti-cancer drugs.8'" Cytochrome P450 metabolism of compounds may result in either activation or detoxification.
The main cytochromes P450 participating in the metabolism of xenobiotics are families 1, 2, and 3, which are primarily located within the liver, although specific forms of cytochrome P450 are expressed in particular extrahepatic tissues. For example, members of the cytochrome P450 family 3 are present in high concentration in small intestinal epithelium and it has been suggested that they protect the small intestine from carcinoma. 12 Indeed, it has recently been suggested that an absence from the colon of certain of these enzymes, especially specific forms of cytochrome P450, may be involved in the comparatively high incidence rate of carcinogenesis in this organ. '3 One type of product of cytochrome P450 mediated metabolism are potentially toxic epoxides. These can be converted to comparatively less toxic trans-dihydrodiols by a group of enzymes known as epoxide hydrolases, '4 although subsequent oxidation can lead to the formation of diol epoxide derivatives, which are more toxic than their parent compounds. Epoxide hydrolases are mainly located within the smooth endoplasmic reticulum (microsomal fraction of subcellular homogenate).
Toxic electrophilic compounds produced by both cytochromes P450 and microsomal epoxide hydrolases can be eliminated from the body by conjugation with glutathione. This conjugation reaction is catalysed by another complex gene family, the glutathione S-transferases. The three main groups of glutathione S-transferases are a (basic), ,u (neutral), and a (acidic), mainly present in the liver, but also present in various extrahepatic tissues'5 including intestinal epithelium. Recent studies have suggested an increased activity of expression of glutathione S-transferases in colonic tumour cells compared with normal non-neoplastic mucosa. 6 As the expression of different xenobiotic metabolising enzymes may take part in both the development of colonic neoplasia and drug resistance of established colonic carcinomas we have investigated the expression of cytochromes P450 IA and 3A, epoxide hydrolase, and glutathione S-transferases a, [t, and a in normal colon, colonic adenomas, and adenocarcinoma of the colon.
Methods

ANTIBODIES
Cytochrome P450 IA was identified using a murine monoclonal antibody (RM3) as des-cribed previously.'7 Cytochrome P450 3A was also identified using a monoclonal antibody (HL3), which has been raised and characterised in our laboratories. 9 Microsomal epoxide hydrolase was recognised using a rabbit polyclonal antibody raised in our laboratories against a purified preparation of human hepatic microsomal epoxide hydrolase.20 Cytoplasmic forms of glutathione S-transferases a, ri, and a were recognised using rabbit polyclonal antibodies purchased from Novocastra Laboratories, Newcastle upon Tyne. All the antibodies used in this study recognise epitopes that are resistant to formalin fixation and wax embedding. Twelve colonic adenoma biopsy specimens were examined, of which six were tubular adenomas, three were villous adenomas, and three were tubulovillous adenomas. All 12 (100%) were found to show positive immunostaining for both forms of cytochrome P450, cytochrome P450 IA, and cytochrome P450 3A. This was also the case for three other enzymes, epoxide hydrolase, glutathione S-transferase a, and glutathione S-transferase it, where all the tumours showed positive immunoreactivity.
Glutathione S-transferase [t, however, was expressed in 10 (83%) of the tumours (Tables I  and II) .
For each enzyme, immunoreactivity was present in the cytoplasm of tumour cells (Fig 1) . In areas of villous adenoma some of the tumour cells also showed nuclear immunoreactivity (Fig  2) . Mucus secretory cells did not show any immunoreactivity.
COLONIC CARCINOMAS
Twenty eight colonic carcinoma tumours were examined, all ofwhich were moderately differentiated adenocarcinomas. There were three Dukes's grade A carcinomas, 13 Dukes's grade B tumours, and 12 Dukes's grade C adenocarcinomas. Based on immunoreactivity, all the carcinomas expressed at least one enzyme, and six tumours expressed all six enzymes (Table II) .
Twenty one (75%) of the carcinomas showed positive immunostaining for cytochrome P450 1A, with 17 (61%) showing positive immunostaining for cytochrome P450 3A. Epoxide hydrolase immunoreactivity was present in 25 (89%) of the tumours, 20 (71%) showed positive immunostaining for glutathione S-transferase a, whereas both glutathione S-transferases [t and a were detected in 17 (61%) of the tumours (Table  II) .
Immunostaining for each enzyme was present in the cytoplasm of tumour cells (Figs 3 and 4) , although in a few cases nuclear staining was also seen for the glutathione S-transferases. The There were no significant correlations between enzyme expression and Dukes's grade.
Discussion
The development of carcinoma of the colon is dependent on both genetic and environmental factors and its is generally accepted that the development of colonic carcinoma follows the adenoma-carcinoma sequence. The presence in the diet of carcinogens or pro-carcinogens is probably one important environmental factor and these carcinogens and pro-carcinogens can be either activated or deactivated by xenobiotic metabolising enzymes present in the colon. Some of these compounds may already have had metabolism in the liver or small intestine, or both, before reaching the colon by biliary excretion. We have studied the localisation by immunohistochemistry of different forms of the drug metabolising enzymes, cytochrome P450, epoxide hydrolase, and glutathione S-transferase in normal colon, and benign and malignant epithelial tumours of the colon.
Although There has been only one report that has identified epoxide hydrolase in colonic carcinomas,22 by western blot analysis. The high frequency of expression of epoxide hydrolase seems to be a fairly general phenomenon of carcinomas as we have also identified frequent expression of epoxide hydrolase in carcinomas of the breast20 and liver. 26 The expression in colonic carcinomas of different forms of glutathione S-transferase has been investigated in several biochemical studies.
All reports using 1l-chloro-2,4-dinitrobenzene as a substrate for total glutathione S-transferase activity have pointed to the presence of glutathione S-transferase activity in homogenates of colonic carcinomas.' 2222325 Western blots have shown glutathione S-transferase u to be the form most frequently present.24 This finding is supported by the results of Howie et al,23 who used a radioimmunoassay to measure the activity of glutathione S-transferase n expression. These data must be interpreted cautiously, however, in view of our findings that glutathione S-transferase it is present in normal colonic epithelium and also in chronic inflammatory cells, which are often found as part of colonic carcinomas. We, however, found glutathione S-transferase a to be the most frequently expressed form of glutathione S-transferase in colon carcinomas. This is in contrast with Moorghen et al,' who reported the presence of glutathione S-transferase a in 100% ofsamples, and glutathione S-transferase a in only 10% of tumour samples, by immunohistochemistry with an immunoperoxidase staining method. As shown above, direct comparison between the different types of investigation used is not possible and only immunohistochemical techniques provide direct demonstration that the tumour cells do indeed contain xenobiotic metabolising enzymes.
In conclusion, we found normal colonic mucosa to be characterised by a low frequency of expression of various xenobiotic metabolising enzymes, with cytochrome P450 IA being undetectable. In contrast, colonic adenomas were found to exhibit a very high frequency of expression of specific forms of cytochrome P450, epoxide hydrolase, and glutathione S-transferase. The overall phenotypic expression of different xenobiotic metabolising enzymes in colonic carcinomas is complex. The frequent expression of the various xenobiotic metabolising enzymes may contribute to the anticancer drug resistance that is characteristic of carcinoma of the colon,27 28 and also to chemical carcinogenesis in the colon as these enzymes can metabolise both exogenous'0 and endogenous29 compounds, which are implicated in the development of colon cancer.
